Researchers at The Institute of Cancer Research, London identified the CIP2A–TOPBP1 complex as a master regulator of DNA repair during mitosis, coordinating backup pathways that protect chromosomes ...

Johnson & Johnson today announced Tony Hunter, Ph.D., of the Salk Institute as the recipient of the 2025 Dr. Paul Janssen ...

Understanding why cancer cells rely on specific genes is critical for designing effective targeted therapies. A new study ...

A class of ultrasmall fluorescent core-shell silica nanoparticles developed at Cornell is showing an unexpected ability to ...

“We are encouraged by the emerging data from our lung cancer programs, where systemically delivered Olvi-Vec continues to ...

Cannabidiol (CBD), a non-intoxicating compound in marijuana, “holds substantial promise as an anti-tumor agent” in addition to its other anti-inflammatory properties, a new scientific review ...

Think about your morning rush: chai in one hand, phone in the other, no time for a full workout. What if 10 minutes of sweat ...

A class of ultrasmall fluorescent core-shell silica nanoparticles developed at Cornell is showing an unexpected ability to rally the immune system against melanoma and dramatically improve the ...

The FDA approval of denileukin diftitox (Lymphir) marked a significant shift in this paradigm. As a first-in-class immunotoxin, it employs a dual-action mechanism: directly targeting interleukin-2 (IL ...

According to the registration form, Aktis intends to use a large portion of the IPO proceeds on the two programmes. Around ...

A research team at Oregon Health & Science University (OHSU) has discovered a promising new drug combination that may help people with acute myeloid leukaemia overcome resistance to one of the most ...